Videos

Experts explain how they would choose between combination therapy regimens for patients with metastatic or locally advanced urothelial carcinoma if the choice of treatment was not influenced by low supply availability.

Key opinion leaders discuss the available data on combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma and an FGFR mutation.

Key opinion leaders provide insight on testing strategies, primarily circulating tumor DNA, in patients diagnosed with HR+/HER2- metastatic breast cancer.

Opening their program on HR+/HER2- metastatic breast cancer, expert oncologists consider the growing list of therapeutic targets to test for in patients with early or late-stage disease.

Ritu Salani, MD, offers advice for community oncologists treating patients with cervical cancer and discusses the future directions of the treatment landscape.

A gynecologic oncologist discusses second-line treatment options for patients with recurrent or metastatic cervical cancer, and provides insights on toxicity management.

An overview of first-line treatment options and immune checkpoint inhibitors in metastatic cervical cancer.

Ritu Salani, MD, offers clinical insights on the role of biomarker testing in treating cervical cancer.

An expert gynecologic oncologist reviews the biology of cervical cancer and discusses how HPV vaccination is increasingly playing a role in prevention.

Ritu Salani, MD, presents the case of a patient with cervical cancer and describes the typical disease presentation and risk factors.

Ghassan K. Abou-Alfa, MD, discusses the phase 3 RATIONALE-301 trial of frontline tislelizumab vs sorafenib in patients with hepatocellular carcinoma.

Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.

Amy Dezern, MD, MHS, explains the importance of proper dose titration for luspatercept in the treatment of MDS.

Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.

Sia Daneshmand, MD on the non-muscle invasive bladder cancer treatment paradigm.

Yuri E. Nikiforov, MD, PhD, discusses improvements in diagnosis of thyroid cancer including the classification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ASCO Annual Meeting.

The Oncology Brothers, joined by Muhammad Shaalan Beg, MD, share their thoughts on data from the IMbrave050 trial investigating adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma.

A review of recent data from NAPOLI-3 comparing the NALIRIFOX chemotherapy regimen versus nab-paclitaxel plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma.

Expert oncologists review recent data from the NORPACT-1 study on the use of neoadjuvant FOLFIRINOX chemotherapy for patients with resectable pancreatic head cancer.

Muhammad Shaalan Beg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from the PROSPECT trial investigating neoadjuvant therapy regimens for the treatment of locally advanced rectal cancer.

Edwin Choy, MD, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor.

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

A closer look at disease modifying treatments in MDS, providing insights into their mechanisms of action and impact on the management of the disease.

Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.

Expert oncolgists examine 1-year follow-up data from the IMerge trial, discussing the durability of response (transfusion independence), the impact of imetelstat on hemoglobin levels, key safety outcomes and managing cytopenias.

Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.

Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.